0
2021
Rna Based Therapeutic Market

RNA Based Therapeutic Market

by Disease Type (RNA interference (RNAi) and RNA antisense), Application (Genetic Disorders and Auto Immune Disorders) and End User (Research Institutes, and Hospitals & Clinics): Global Opportunity Analysis and Industry Forecast, 2021-2030

Report Code: A00443
Pages: 170
Dec 2021 | 24892 Views
Author(s) : Vikita Thakur, Swapna Singh , Onkar Sumant
Tables: 116
Charts: 31
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Rna Based Therapeutic Market

Request Now !

RNA Based Therapeutics Market Overview 2030

The global RNA based therapeutics market size generated $4,938.38 million in 2021, and is projected to reach $25,121.95 million by 2030, growing at a CAGR of 17.6% from 2021 to 2030. RNA based therapeutics has garnered significant attention in the recent years due to its potential to treat variety of chronic diseases such as cancer, diabetes, AIDS, tuberculosis and certain cardiovascular conditions also rare and genetic disorders. Despite being in the clinical research phase, the RNA based therapeutics has been explored as a promising treatment option for the diseases which are difficult to treat. Development of this therapeutics is based on promising technologies such as RNA interference technology (RNAi), antisense technology and SMaRT technology. RNAi technology and antisense technology together are gaining prominence in the research industry, as these technologies provide base sequence to develop RNA drugs. 

The RNA based therapeutics market is expected to be negatively impacted by the COVID-19 pandemic. Owing to decline in number of patients visits in hospitals and clinics for RNA based therapies which lead to decline in the demand of RNA based therapeutics products. For instance, SPINRAZA ( RNA based therapeutic product ) had registered a decline in net sales by 3% in 2020 as compare to previous year.

RNAi technology works by causing destruction of specific mRNA molecules, whereas antisense technology works by synthesizing strand of RNA from known gene sequence. These newly synthesized RNA strands then bind to mRNA and makes mRNA inactive. Gene silencing potential of RNA based therapeutics is the primary driver for the growth of this market. The other drivers include target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models that enable companies to reduce the research cost. However, critical issues in drug delivery, high cost of research, and high failure rates are some of the major hurdles for the companies working in this field. Despite the restraints, RNA based therapeutics has the potential to grow due to increasing interest exhibited by the pharmaceutical industries for the commercialization of these therapies.

RNA-Based-Therapeutics-Market

The RNA based therapeutics market is segmented on the basis of type, application, end user and region. Based on type, the market is segmented into RNA interference (RNAi) technologies and RNA antisense technologies. Based on application, the market is segmented into genetic disorders and auto immune disorders. Based on end user, the RNA based therapeutics market is segmented into research institutes, and hospitals & clinics. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

COVID-19 Pandemic on the RNA Based Therapeutics Market

Coronavirus (COVID-19) was discovered in December 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans. 

After its discovery in Wuhan, the disease rapidly spread to other parts of the globe. Moreover, this virus causes various symptoms in patients, which range from common symptoms to serious symptoms. For instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement.

Furthermore, the virus has high potential of lethality in geriatric population. On March 11, 2020, the World Health Organization made an assessment that COVID-19 can be characterized as pandemic. In addition, only a few vaccines that received emergency approvals for COVID-19 prevention. Thus, social distancing is observed as the most important measure to stop the spread of this disease. Furthermore, to maintain social distancing, various countries across the world have adopted nationwide lockdowns. 

Almost every nation is dealing with the outbreak. Most markets are experiencing a decline, owing to the outbreak. The COVID-19 pandemic is an unprecedented global public health challenge and is anticipated to have a negative impact on the RNA based therapeutics market, mRNA vaccines could potentially provide long-term solutions all over the world for diseases ranging from influenza to AIDS, but due to lockdown and temporary closure of research institutes and academic research, the RNA based therapeutics has decreased. Due to lockdowns and stay-at-home orders, people’s lifestyles have become even more sedentary and worse than before, public health recommendation i.e., closure of small laboratories and research centers to prevent SARS-COV-2 spread have the potential to reduce RNA based therapeutics research. The results shed light on the financial fragility of many RNA based therapeutics key players companies. 

By Type Segment Review

Depending on type, the market is divided into RNA interference (RNAi) and RNA antisense. RNA antisense segment is projected to witness fastest growth during the forecast period, owing to increase in revenue of RNA antisense drug discovery and therapeutics. 

RNA Based Therapeutic Market
By Type

Your browser does not support the canvas element.

RNA Antisense segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Application Segment Review

By application, the RNA based therapeutics market is segmented into genetic disorders and auto immune disorders. Genetic disorders segment accounted for a majority of market share in the global RNA based therapeutics market in 2020 and expected to remain dominant during the forecast period, owing to surge in case of genetic diseases, rare disorders, and molecular diagnostics. These factors are expected to further fuel the demand for RNA based therapeutic.

RNA Based Therapeutic Market
By Application

Your browser does not support the canvas element.

Genetic Disorder segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

End User Segment Review

Depending on end user, the market is categorized into research institutes, and hospitals & clinics. The research institutes segment is projected to show fastest growth during the forecast period, due to the collaboration of research organizations and academic research institutes or collaborating with government bodies to bear the high cost of research.

RNA Based Therapeutic Market
By End User

Your browser does not support the canvas element.

Research Institutes holds a dominant position in 2020 and continue to maintain lead in the forecast year

Get more information on this report : Request Sample Pages

Region segment review

By region, the RNA based therapeutics market is analyzed across North America, Asia-Pacific, Europe, and LAMEA. North America dominated the market in 2020, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. The research activities for RNA-based therapeutics are rising in North America due to significant infrastructure for developmental research, availability of substantial research funds and growing government initiatives toward RNA based therapeutics are anticipated to drive the RNA based therapeutics market growth.

RNA Based Therapeutic Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

North America holds a dominant position in 2020 and continue to maintain lead in the forecast year

Get more information on this report : Request Sample Pages

This report provides comprehensive competitive analysis and profiles of prominent RNA based therapeutics market players such as Alnylam Pharmaceuticals, Inc., Silence Therapeutics plc, Arbutus Biopharma Corporation, Genzyme (Sanofi), Ionis Pharmaceuticals, Sarepta Therapeutics, Benitec Biopharma Inc., Arrowhead Pharmaceuticals, Biogen, Inc. and Gradalis, Inc.

Key Benefits for Stakeholders

  • This report provides a detailed quantitative analysis of the current RNA based therapeutics market trends and forecast estimations from 2020 to 2030, which assists to identify the prevailing market opportunities. 
  • An in-depth market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
  • A comprehensive analysis of factors that drive and restrain the growth of the global is provided.
  • The projections in this report are made by analyzing the current trends and future market potential from 2021 to 2030, in terms of value.
  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
  • Key market players within the RNA based therapeutics market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of the RNA based therapeutics market.

RNA Based Therapeutic Market Report Highlights

Aspects Details
BY TYPE
  • RNA Interference (RNAi)
  • RNA Antisense
BY APPLICATION
  • Genetic Disorders
  • Auto immune disorders
BY END USER
  • Research Institutes
  • Hospitals & Clinics
BY REGION
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Australia, Japan, China, India, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Alnylam Pharmaceuticals, Inc., Silence Therapeutics plc, Arbutus Biopharma Corporation, Genzyme (Sanofi), Ionis Pharmaceuticals, Sarepta Therapeutics, Benitec Biopharma Inc., Arrowhead Pharmaceuticals, Biogen, Inc, Gradalis, Inc.
 

Loading Table Of Content...


 
 

In accordance with several interviews conducted, top-level CXOs agree that the utilization of RNA based therapeutics is anticipated to witness a significant rise with technological advancements and increase in prevalence of genetic disorders. Recent innovations and constant development in this field have fuelled the market growth, also Increase in interest of healthcare providers owing to several benefits offered by RNA based therapeutics is boosting the market.

According to the CXOs, increase in economic strength of the developing nations, such as Japan, China, India, Indonesia, Thailand, and others as well as rise in healthcare expenditure are expected to drive the market growth during the forecast period.

Rapid growth was observed in the adoption of advance sequencing technologically across developing economies, and this is expected to offset the challenging conditions in mature markets such as North America and Europe. Moreover, North America and Europe are expected to dominate during the forecast period, while emerging countries in Asia-Pacific and Latin America are expected to offer significant growth opportunities.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The total market value of RNA Based Therapeutics Market is $25,121.95 Million in 2030

A. The forecast period in the report is from 2021 to 2030

A. The market value of RNA Based Therapeutics in 2020 was 4,938.38 million in 2020

A. The base year for the report is 2020

A. Yes, RNA Based Therapeutics Market companies are profiled in the report

A. The top companies that hold the market share in RNA Based Therapeutics Market are Ionis Pharmaceuticals, Anlyam Therapeutics, Sarepta Therapeutics, Arrowhead Therapeutics

A. No, there is no value chain analysis provided in the RNA Based Therapeutics Market report

A. The key trends in the RNA Based Therapeutics Market areincrease in prevalence of chronic disease along with rise in elderly population are the key factors driving the market growth.t

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Free Sample

OR

Purchase Full Report of
Rna Based Therapeutic Market

Start reading instantly.
This Report and over 18,822+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Dec 2022 - Dec 2023)
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Dec 2022 - Dec 2023)
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Dec 2022 - Dec 2023)
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Dec 2022 - Dec 2023)
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Dec 2022 - Dec 2023)
  • Library
    Membership

  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers